Metabolon and SYNLAB Group Form Commercialization Collaboration for Quantose™ IR Diagnostic
March 29, 2016 09:59 ET
|
Metabolon, Inc.
SYNLAB Group to market Quantose IR, a laboratory-developed test used to identify insulin resistanceInitial launch in SpainAdditional markets to follow in 2016 RESEARCH TRIANGLE PARK, N.C., March 29,...
WellDoc® Announces Strategic Collaboration With LifeScan to Deliver Best-in-Class Digital Health Solution for Patients Living With Type 2 Diabetes
March 01, 2016 08:00 ET
|
WellDoc Inc.
BALTIMORE, Md., March 01, 2016 (GLOBE NEWSWIRE) -- WellDoc, a digital health technology leader, today announced a collaboration with LifeScan, Inc., a business within the Johnson & Johnson...
Project HOPE and Boston Scientific Launch New Program in Jharkand State of India against Noncommunicable Diseases
February 29, 2016 17:30 ET
|
Project HOPE
MILLWOOD, Va., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Project HOPE, the global health education and humanitarian assistance organization, today is launching a new initiative in the Ranchi District of...
WellDoc® Publishes Framework for Developing Digital Therapeutics Programs That Improve Chronic Disease Outcomes
February 24, 2016 13:00 ET
|
WellDoc Inc.
BALTIMORE, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Digital health technology leader WellDoc today announced that a manuscript outlining its framework for creating digital therapeutics technologies to...
Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte Biotech's Type 1 Diabetes Treatment
February 08, 2016 09:00 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - February 08, 2016) - Johnson & Johnson (J&J), like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1...
Xeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD Meeting
February 04, 2016 10:22 ET
|
Xeris Pharmaceuticals, Inc.
Austin, TX, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) will present data from a human factors study with its G-PenTM glucagon auto-injector during the 9th International...
Helmsley Charitable Trust Awards $3.4 Million to DreaMed Diabetes for Type 1 Diabetes Decision Support
February 03, 2016 16:22 ET
|
The Leona M. and Harry B. Helmsley Charitable Trust
NEW YORK, N.Y., Feb. 3, 2016 (GLOBE NEWSWIRE) -- The Type 1 Diabetes Program of The Leona M. and Harry B. Helmsley Charitable Trust today announced a $3.4 million grant for DreaMed Diabetes (DreaMed)....
Xeris Pharmaceuticals Announces $41 Million Series C Financing
January 07, 2016 10:24 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of...
ALRT Introduces Value Pricing for Diabetes Management
December 22, 2015 09:25 ET
|
ALR Technologies
RICHMOND, Va., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Medical practices, health insurers, self-insured employers, and other potential users of the ALRT diabetes management system can now choose a pricing...
WellDoc® Raises $22 Million in Series B Funding From Samsung Ventures, Merck Global Health Innovation Fund and Other Leading Venture Groups
December 17, 2015 08:00 ET
|
WellDoc Inc.
BALTIMORE, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Digital health technology leader WellDoc today announced the completion of a $22 million Series B financing. Samsung Ventures acted as the lead...